The dawn of a new era for nonalcoholic fatty liver disease?

Alessandro Mantovani, Chiara Zusi


Non-alcoholic fatty liver disease (NAFLD) has become the most frequent chronic liver disease in several developed and developing countries, affecting roughly 30% of adults in the general population, 65–70% of individuals with type 2 diabetes mellitus and, virtually, all patients with obesity (1). Of note, its prevalence is believed to rise dramatically over the next decade, along with an increase of prevalence in obesity, diabetes mellitus and metabolic syndrome.